A study published in the New England Journal of Medicine found that the popular drug does not decrease the chances of being hospitalized due to COVID-19.
This COVID-19 antibody-drug is unlikely to be effective against the notorious Omicron subvariant known as BA.2
Virus team visits China lab as poorer nations get vaccine boost
Several lots of Excedrin were recalled because they could have holes in the bottle that would give children to access the product inside.
Sanofi, GSK Covid vaccine delayed until end of 2021
Narcolepsy fiasco spurs Covid vaccine fears in Sweden
Sanofi and GSK expect to begin Phase 1/2 trials of a COVID-19 vaccine in September, with Phase 3 clinical trials beginning at the end of 2020.
UK signs up for Sanofi-GSK coronavirus vaccine
Novartis to pay $336 mn in US settlements on bribes
Sanofi is also developing potential coronavirus vaccines with English pharmaceutical company GlaxoSmithKline Plc.
GSK Consumer Healthcare has recalled children's cough syrup because the dosing cups were improperly marked, which could potentially cause an overdose of the medication.
GSK Consumer Healthcare has recalled five lots of Benefiber fiber supplement powder because it may have green plastic pieces from the bottle cap inside the bottle.
Two types of Excedrin migraine medications have had their production suspended for this reason.
Drug makers have increased prices on over 200 drugs, including some of those used for cancer, HIV, arthritis and lung disease. Increases take effect on January 1st.
Pharmaceutical companies compete to launch a vaccine for the mosquito-borne virus.
The new company, named Galvani Bioelectronics, will focus on research, development and commercialization of “bioelectronic” medicines.
The move marks the first partnership with a drug company for ResearchKit, Apple Inc.’s medical platform for studies and clinical trials.
Aiming to tap the ever-growing Chinese market, the drugmaker on Wednesday opened a research and development campus in Shanghai.
David Epstein is the second high-ranking official to exit the pharmaceutical company within months.
In the three-month period ending March 31, sales of Gleevec — hurt by the launch of a cheaper generic version in the U.S. in February — fell 22 percent.
The White House said the president is expected to sign the legislation although it is insufficient to meet the challenge.
The U.K. is fining GlaxoSmithKline for the "pay-for-delay" tactic, which drug companies have deployed in recent years to stifle generic competition.
The deals, which include an upfront payment of $350 million, will help the British drugmaker compete with its American rival Gilead Sciences.
A new analysis of Paxil reveals there was a greater risk to teens of severe side effects from the antidepressant — including suicidal thoughts and self-harm.
The plant, which employs about 850 people, was shut down temporarily after bacterium that causes the disease was found in a cooling tower.